Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
Natera announced it will present 21 studies, including seven oral presentations, at the upcoming American Transplant Congress highlighting the clinical utility of its Prospera test for transplant monitoring. New data from the PEDAL study of 346 patients indicates that elevated Prospera dd-cfDNA levels in biopsy-negative cases were strongly predictive of adverse outcomes, showing >6X higher rates of graft loss.
Key figures
- Ddcfda threshold
- <0.5%
- Pedal patient count
- 346
- Pedal positive rate
- 18.2%
- Presentations count
- 21
- Proactive patient count
- 989
- Graft loss rate increase
- >6X
- Oral presentations count
- 7
- Rejection odds reduction
- ~12X
- Graft loss odds reduction
- ~5.5X
- Peer reviewed publications
- >400
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.